Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
Additionally, the recently completed Phase II study, HBCO, which investigated pomaglumetad methionil as an adjunctive treatment with atypical antipsychotics, did not meet its primary endpoint.
Lilly is contacting study investigators to outline specific actions related to the close-out of each ongoing study. Lilly will work with study investigators to ensure an appropriate transition of study participants to continuing clinical care outside of the trials.
"I'm disappointed in what these results mean for patients with schizophrenia who still are searching for options to treat this terrible illness," said
The decision to stop ongoing Phase III development of pomaglumetad methionil is expected to result in a third-quarter charge to R&D expense in the range of
About Lilly's Pipeline
Lilly currently has a number of unique potential medicines in its Phase III clinical development pipeline, representing a variety of therapeutic areas including diabetes (4), cancer (3), neuroscience (2) and autoimmune diseases (2). To learn more about the molecules in Lilly's clinical development pipeline, please visit Lilly's interactive pipeline website available at Lilly.com/pipeline.
About
Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in
This press release contains forward-looking statements about the impact of ending studies of pomaglumetad methionil for the treatment of schizophrenia, and reflects Lilly's current beliefs. The financial information included in this release is an estimate only. For further discussion of risks and uncertainties affecting the company's business, see Lilly's filings with the
P-LLY
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
SOURCE
News Provided by Acquire Media